In this Article, the affiliations of authors Michael Quinn and Orla McNally should read “22Department of Obstetrics and Gynaecology, The University of Melbourne, and The Royal Women’s Hospital, Parkville, Victoria 3052, Australia”. Their affiliations have been corrected in the HTML and PDF versions online.
Author information
Consortia
Additional information
The online version of the original article can be found at 10.1038/nature14410
Rights and permissions
About this article
Cite this article
Patch, AM., Christie, E., Etemadmoghadam, D. et al. Correction: Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer. Nature 527, 398 (2015). https://doi.org/10.1038/nature15716
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature15716
This article is cited by
-
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
npj Precision Oncology (2024)
-
Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role
Medical Oncology (2023)
-
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Nature Communications (2017)
-
Cytotoxic and targeted therapy for hereditary cancers
Hereditary Cancer in Clinical Practice (2016)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.